Immunovant (NASDAQ:IMVT) Given “Buy” Rating at Guggenheim
Guggenheim reissued their buy rating on shares of Immunovant (NASDAQ:IMVT – Free Report) in a research report sent to investors on Thursday,Benzinga reports. A number of other brokerages have also recently weighed in on IMVT. Bank of America reduced their price target on shares of Immunovant from $38.00 to $33.00 and set a “buy” rating […]
Guggenheim reissued their buy rating on shares of Immunovant (NASDAQ:IMVT – Free Report) in a research report sent to investors on Thursday,Benzinga reports. A number of other brokerages have also recently weighed in on IMVT. Bank of America reduced their price target on shares of Immunovant from $38.00 to $33.00 and set a “buy” rating […]
